FDA draws the compounding line, semaglutide's $274 Medicare price, and the Bridge's taxpayer math.

The FDA sent Empower Pharmacy - one of the largest compounding pharmacies in the country - a warning letter dated September 18, saying it made copies of blockbuster weight-loss drugs in "inordinate amounts." It is the first time the agency has weighed in on where legitimate personalized compounding ends and mass-copying of FDA-approved drugs begins. Investigators cited orders with no documented prescriber determination of a "significant difference," other orders where the rationale appeared repeated verbatim, and sheer volume. Empower says it has "already remediated many of the issues" and will keep working with the agency.

Why it matters: the post-shortage gray zone is closing. Practices sourcing compounded GLP-1s should expect more scrutiny of the supply chain, not less - and documented, compliant sourcing keeps you on the right side of it.

Source: CBS News, September 24, 2026

The American Med Spa Association's read of the Empower letter: the FDA is examining how the "medical necessity" exception is used in practice. The exception is patient-specific - a prescriber must determine that a change produces a significant difference for an identified patient. It is not a blanket authorization to compound GLP-1s. The letter also questions the assumption that adding ingredients like B12 or niacinamide automatically creates a qualifying difference, and notes that cost alone is generally not sufficient justification.

Why it matters: if your protocols rely on compounded GLP-1s, documentation has to reflect individualized clinical judgment and withstand regulatory review. Boilerplate rationales copied across prescriptions are exactly what investigators flagged.

Source: American Med Spa Association, September 24, 2026

With about 700,000 seniors started on GLP-1s since July 1 under the Medicare GLP-1 Bridge, the cost split is getting clearer: patients pay a $50 monthly copay, manufacturers supply the drugs at a net $245, and Medicare covers the remaining $195 per patient per month. KFF projects the program could cost between $1.3B and $10B over its 18-month life depending on take-up, and Lilly says as many as 20 million Medicare patients could qualify. Lilly also broke ground on a $6.5B Houston plant to make the active ingredient for its oral pill Foundayo.

Why it matters: government channels are absorbing the price-sensitive end of the market at scale. Cash-pay practices compete on service, speed and total cost of care - and the manufacturers are building for volume that assumes this channel mix is permanent.

Source: IBTimes, September 24, 2026

CMS's negotiated maximum fair price for semaglutide products takes effect for Medicare Part D on January 1, 2027: $274 for a 30-day supply, down 71% from the 2024 list price of $959. Broken out, that is $276.78 for a monthly Ozempic pen or a month of Rybelsus tablets, and $385.63 for a four-pen box of Wegovy. Semaglutide was the single highest-spending drug in the negotiation round - $15.2B in 2024 Part D costs across 2.28 million enrollees.

Why it matters: the branded reference price keeps ratcheting down. Every step down resets what patients and payers consider a "normal" monthly price - plan your 2027 positioning around it now.

Source: The Financial Wire, September 19, 2026

- Novo Nordisk licensed a once-weekly oral GLP-1/GIP dual receptor agonist (HRS-1596) from China's Hengrui Pharma - the oral pipeline keeps crowding. (Axcess News, September 29, 2026)
- Paraguay became the first South American country to approve Lilly's oral orforglipron. (Streamline, September 18, 2026)
- Earlier this month the FDA issued five warning letters over peptide and GLP-1-related products - enforcement is broadening beyond the biggest players. (Spakinect, September 15, 2026)